Shares of Dyne Therapeutics, Inc. (DYN) plunged 5.22% in the intraday session on Monday, following the company's disappointing Q4 2024 earnings report last week.
The biotech firm reported a higher-than-expected loss of $0.88 per share for the quarter ended December 31, 2024, missing analysts' average estimate of a $0.96 loss per share. Revenues for the quarter came in at zero, in line with expectations.
The wider losses appear to have dampened investor sentiment, sparking a selloff in Dyne's shares. The stock has already fallen a staggering 42.2% so far this quarter amid concerns over the company's cash burn and ability to bring new therapies to market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。